Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesTransplantBCBS Massachusetts Liver Transplant Coverage | Ope…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - MassachusettsPolicy 198

    Liver Transplant and Combined Liver-Kidney Transplant

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 198 alerts

    Get alerted when Policy 198 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity, investigational status, exclusions, coding, and prior authorization for liver transplantation, liver retransplantation, and combined liver-kidney transplantation for adult and pediatric commercial members. It applies to managed care, PPO, and indemnity products.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyLiver Transplant and Combined Liver-Kidney Transplant
    Policy CodePolicy 198
    Change TypeModified
    Effective DateFeb 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification or prior authorization for inpatient services described in this policy for all products.
    SourceLink
    POLICY UPDATE CHANGES

    The February 2026 policy update classified unresectable colorectal liver metastases, hepatic epithelioid hemangioendothelioma, hepatic adenomas, and intrahepatic cholangiocarcinoma as investigational indications for liver transplantation and clarified that the policy applies to adults and children.

    CPT 47135Covered procedure
    9Investigational or not-covered situations
    All productsInpatient authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Adult and pediatricCovered populations
    2Transplant types
    3 monthsMinimum abstinence period

    Covered and Investigational Transplant Services

    Liver transplantation for end-stage liver failure

    A liver transplant using a cadaver or living donor may be considered medically necessary for carefully selected individuals with end-stage liver failure due to an irreversibly damaged liver.

    Qualifying end-stage liver disease etiology

    • Hepatocellular diseases: Alcoholic liver disease; viral hepatitis A, B, C, or non-A/non-B; autoimmune hepatitis; alpha-1 antitrypsin deficiency; hemochromatosis; metabolic dysfunction-associated steatohepatitis (MASH); protoporphyria; or Wilson disease.
    • Cholestatic liver diseases: Primary biliary cirrhosis; primary sclerosing cholangitis with development of secondary biliary cirrhosis; or biliary atresia.
    • Other listed etiologies: Budd-Chiari syndrome; primary hepatocellular carcinoma; inborn errors of metabolism; trauma and toxic reactions; familial amyloid polyneuropathy; amyloidosis; cryptogenic cirrhosis; end-stage liver disease in children; familial cholestasis; or intrahepatic bile duct paucity (Alagille syndrome).

    Polycystic liver disease

    Liver transplantation may be considered medically necessary when polycystic liver disease causes massive hepatomegaly and one of the following complications is present.

    Polycystic liver disease criteria

    • Complication: Enlargement of the liver impinges on respiratory function; enlargement is extremely painful; or enlargement significantly compresses and interferes with the function of other abdominal organs.At least 1

    Hilar cholangiocarcinoma or pediatric hepatoblastoma

    Liver transplantation may be considered medically necessary for the following conditions.

    Additional qualifying conditions: The individual has unresectable hilar (extrahepatic) cholangiocarcinoma or is a pediatric patient with nonmetastatic hepatoblastoma.

    Liver retransplantation

    Liver retransplantation may be considered medically necessary when one of the following conditions is present.

    Retransplantation indication: The individual has primary graft nonfunction; hepatic artery thrombosis; chronic rejection; ischemic-type biliary lesions after donation after cardiac death; or recurrent non-neoplastic disease causing late graft failure.

    Combined liver-kidney transplantation

    Combined liver-kidney transplantation may be considered medically necessary when both requirements are met.

    • Liver transplant qualification: The individual meets applicable medical necessity criteria for liver transplantation.
    • Kidney disease: The individual has advanced irreversible kidney disease.

    Investigational liver transplantation

    Liver transplantation is investigational for the following situations.

    Investigational indications: The individual has intrahepatic cholangiocarcinoma; neuroendocrine tumors metastatic to the liver; hepatic adenoma; unresectable colorectal liver metastases; epithelioid hemangioendothelioma (HEHE); hepatocellular carcinoma that has extended beyond the liver; or ongoing alcohol and/or drug abuse.

    Evidence for abstinence may vary among transplant programs, but generally a minimum of 3 months is required.

    Other situations

    Liver transplantation is investigational in all other situations not described above.

    Unlisted situations: The proposed liver transplantation indication is not described in the policy's medically necessary criteria.

    Coverage is not provided for known current malignancy, including metastatic cancer.

    Coverage is not provided for a recent malignancy with a high risk of recurrence. The transplant team must assess recurrence risk, and the provider must submit a statement explaining why the patient remains an appropriate transplant candidate.

    Coverage is not provided for an untreated systemic infection that makes immunosuppression unsafe, including chronic infection.

    Coverage is not provided for other irreversible end-stage disease that is not attributed to liver disease.

    Coverage is not provided for a history of cancer with a moderate risk of recurrence.

    Coverage is not provided for a systemic disease that could be exacerbated by immunosuppression.

    Coverage is not provided for psychosocial conditions or chemical dependency that affect the patient’s ability to adhere to therapy. Patients whose liver disease is related to alcohol or drug abuse must be actively involved in a substance abuse treatment program, such as weekly meetings, partial- or full-day programs, or an inpatient program.

    Covered Procedure and Diagnosis Codes

    CPT CodesCPTCovered
    47135Liver allotransplantation; orthotopic, partial or whole, from cadaver or living donor, any age
    ICD-10 Procedure CodesICD-10Covered
    0FB03ZZExcision of Liver, Percutaneous Approach
    0FB00ZZExcision of Liver, Open Approach
    0FB04ZZExcision of Liver, Percutaneous Endoscopic Approach
    0FB10ZZExcision of Right Lobe Liver, Open Approach
    0FB13ZZExcision of Right Lobe Liver, Percutaneous Approach
    0FB14ZZExcision of Right Lobe Liver, Percutaneous Endoscopic Approach
    0FB20ZZExcision of Left Lobe Liver, Open Approach
    0FB23ZZExcision of Left Lobe Liver, Percutaneous Approach
    0FB24ZZExcision of Left Lobe Liver, Percutaneous Endoscopic Approach
    0FT00ZZResection of Liver, Open Approach
    1–10 of 12
    1/2

    Authorization, Documentation, and Coverage Alerts

    Prior Authorization

    Inpatient Prior Authorization Required

    Precertification or prior authorization is required for all products when a service described in this policy is performed in the inpatient setting.

    • Applies to liver transplantation and combined liver-kidney transplantation services described in this policy.
    Prior Authorization

    Product-Specific Outpatient Authorization

    For services described in this policy performed in the outpatient setting, prior authorization requirements vary by product. Verify the member’s product-specific requirements before the procedure.

    • Commercial Managed Care (HMO and POS): check outpatient prior authorization requirements.
    • Commercial PPO and Indemnity: check outpatient prior authorization requirements.

    Liver Transplantation Overview

    Liver transplantation is a treatment of last resort for end-stage liver disease. The graft may come from a deceased donor or may consist of a segment from a living donor. Transplant recipients require lifelong immunosuppression because allograft rejection can occur early or late after transplantation.

    Transplant Allocation and Graft Terms

    Status 1A
    Priority categoryStatus 1A
    Patient populationPatients with acute liver failure
    Life expectancy without transplantationFewer than 7 days
    Status 1B
    Priority categoryStatus 1B
    Patient populationPediatric patients
    Underlying conditionChronic liver disease

    Transplant Candidate Selection

    Transplant candidate selection

    Candidates must meet the applicable transplant medical necessity criteria and must not have an exclusion condition.

    • Qualifying transplant indication: The individual meets criteria for liver transplantation, liver retransplantation, or combined liver-kidney transplantation.
    • No exclusion condition: The individual does not have a policy-listed malignancy, unsafe infection, nonhepatic irreversible end-stage disease, immunosuppression-exacerbated systemic disease, or adherence-limiting psychosocial or chemical-dependency condition.

    Coverage Exclusions and Contraindications

    Transplantation is contraindicated when there is current malignancy, including metastatic cancer; a recent malignancy with a high risk of recurrence; or a history of cancer with a moderate risk of recurrence. For recently treated malignancy, recurrence risk is assessed by the transplant team, and the provider must explain why the patient remains an appropriate transplant candidate.

    Transplantation is contraindicated when an untreated systemic or chronic infection makes immunosuppression unsafe.

    Transplantation is contraindicated when a systemic disease could be exacerbated by immunosuppression.

    Transplantation is contraindicated when psychosocial conditions or chemical dependency affect the patient’s ability to adhere to therapy. Patients with liver disease related to alcohol or drug abuse must be actively involved in a substance abuse treatment program.

    Required Clinical Assessments and Documentation

    Documentation Required

    Complete the malignancy evaluation

    For recently treated malignancy, the transplant team must assess recurrence risk. The provider must submit an explanation of why the patient remains an appropriate transplant candidate.

    • Include the transplant team’s recurrence-risk assessment.
    • Submit the provider’s explanation of continued transplant appropriateness.
    Documentation Required

    Verify active substance-abuse treatment

    Patients whose liver disease is related to alcohol or drug abuse must be actively involved in a substance abuse treatment program. Document participation in an appropriate program, such as weekly meetings, a partial- or full-day program, or an inpatient program.

    • Document active treatment-program participation.
    • Examples include weekly meetings such as Alcoholics Anonymous, partial- or full-day programs, or an inpatient program.
    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyLiver Transplant and Combined Liver-Kidney Transplant
    Policy CodePolicy 198
    Change TypeModified
    Effective DateFeb 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification or prior authorization for inpatient services described in this policy for all products.
    SourceLink
    On This Page
    Covered and Investigational Transplant ServicesCovered Procedure and Diagnosis CodesAuthorization, Documentation, and Coverage AlertsLiver Transplantation OverviewTransplant Allocation and Graft TermsTransplant Candidate SelectionCoverage Exclusions and ContraindicationsRequired Clinical Assessments and Documentation
    Documentation Required

    Recent Malignancy Documentation

    Liver transplantation is not covered for a recent malignancy with high risk of recurrence unless the transplant team supports candidacy. Providers must submit a statement explaining why the patient remains an appropriate candidate for transplantation.

    • The transplant team determines the risk of recurrence for a previously treated malignancy.
    • Include the transplant-team statement with the authorization or coverage documentation.
    Documentation Required

    Substance Abuse Treatment Documentation

    Patients with liver disease related to alcohol or drug abuse must be actively involved in a substance abuse treatment program.

    • Acceptable participation may include weekly meetings such as Alcoholics Anonymous, partial- or full-day programs, or inpatient programs.
    • Evidence of abstinence may vary among liver transplant programs; a minimum of 3 months is generally required.
    Billing Rule

    Coding and Benefit Verification

    Code inclusion or exclusion does not establish member coverage or provider reimbursement. Verify the member’s contract benefits in effect at the time of service and report services with current industry-standard codes.

    • Use the most up-to-date procedure, revenue, and diagnosis codes.
    • Report applicable modifiers.
    • The listed codes are informational only and are not an all-inclusive list.
    • Medical-necessity criteria must be met for the applicable codes to be covered for Commercial members, including Managed Care (HMO and POS), PPO, and Indemnity.

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    MELD and PELD
    MELDModel for End-stage Liver Disease
    PELDPediatric End-stage Liver Disease
    UsePrioritize donor livers after Status 1 and assess mortality risk and severity of illness
    Status 1A allocation priority
    Allocation categoryStatus 1A
    Clinical conditionAcute liver failure
    Expected survival without liver transplantationFewer than 7 days
    Status 1B allocation priority
    Allocation categoryStatus 1B
    Patient populationPediatric patients
    Clinical conditionChronic liver disease
    MELD/PELD scores
    MELDModel for End-stage Liver Disease severity score
    PELDPediatric End-stage Liver Disease severity score
    Allocation usePrioritize liver transplant candidates and donor livers based on mortality risk and illness severity
    Split graft
    Graft typeSplit graft
    Donor organDonor liver
    UseDivided into 2 segments that can be used for 2 recipients